Latest News — Page 4

Big Data Analysis Free account
Portugal Outpatient Medicine Spend Rises 7.9%, Led by Diabetes Drugs
Portugal’s outpatient medicine bill rose 7.9% in January to August 2026. Antidiabetics drove nearly a third of the increase, and semaglutide spend rose 54.5%. #SyenzaNews #MarketAccess #HealthEconomics

Europe Free account
Orphan Medical Devices Pilot Closes With 13 Positive Status Opinions
The EMA orphan medical devices pilot ran from August 2024 to March 2026. All 13 finalised procedures gave positive orphan status advice, and the service is now established. #SyenzaNews #MedTech #MarketAccess

Europe Free account
EMA Expert Panel Advice Pilot Ends With a Streamlined 60-Day Procedure
EMA’s expert panel advice pilot for high-risk medical devices closed in February 2026 with 27 advice procedures finalised. Average advice time fell from 112 days in phase one to 86 in phase two, and a 60-day procedure followed. #SyenzaNews #MedicalDevices #HTA #MarketAccess

Diseases
Individualised gene therapies for rare diseases: FDA draft guidance
The FDA’s draft guidance lets sponsors add new patient-specific variants to one BLA without new trials, while CMS plans to broaden its gene therapy access model.

Clinical Practice
KRAS G12C inhibitor divarasib outperforms approved drugs
The KRAS G12C inhibitor divarasib improved survival versus sotorasib or adagrasib in the phase III Krascendo 1 trial. #SyenzaNews #oncology #NSCLC

Europe
Novartis core operating income rises, 2026 outlook raised
Novartis core operating income rose 10% at constant exchange rates in Q3 2026, and 2026 guidance for the measure was raised. #SyenzaNews #MarketAccess

Clinical Practice
Izalontamab brengitecan breast cancer: 59% lower risk of progression
Phase 3 PANKU-Breast01 data show izalontamab brengitecan cut the risk of disease progression or death by 59% versus chemotherapy in HR-positive, HER2-negative breast cancer. #SyenzaNews #breastcancer #oncology

Clinical Practice
Keytruda Monotherapy Endometrial Cancer: 43% Risk Reduction
Keytruda monotherapy cut the risk of progression or death by 43% against platinum chemotherapy in dMMR endometrial cancer, in the KEYNOTE-C93 Phase 3 trial. #SyenzaNews #oncology #precisionmedicine #endometrialcancer

Europe
Endometriosis and fibroid tablets in England: prescriptions soar
NHS use of NICE-recommended endometriosis and fibroid tablets in England more than tripled in a year, from 1.2 million to 3.7 million tablets. #SyenzaNews #MarketAccess

Clinical Practice
JNJ-6143 prostate cancer: 75% tumor response in Phase 1 trial
JNJ-6143, an investigational first-in-class oral molecule, produced a 75% tumor response rate among patients with measurable disease in a Phase 1 study. #SyenzaNews #prostatecancer #oncology

Clinical Practice
Claudin 18.2 antibody-drug conjugate prolongs survival in gastro-oesophageal cancer
Sone-Ve doubled median overall survival versus investigator’s choice in third-line and later gastro-oesophageal cancer; second-line PFS missed significance.

Diseases
Obesity drug reimbursement in Portugal: new SNS terms
Portaria n.º 464/2026/1 limits state reimbursement for obesity medicines to SNS patients in a hospital obesity pathway. Cover is 15% for 12 months. #SyenzaNews #MarketAccess

Diseases Free account
Antiretroviral Tender Awards Declared Invalid by Pretoria Court
A Pretoria court has declared invalid the antiretroviral tender awards for two items and ordered the health department to redo the split within 120 days. Cipla’s review succeeded on all five grounds, while Hetero’s challenge was dismissed with attorney-and-client costs. #SyenzaNews #SouthAfrica #HIV

Clinical Practice
Intismeran Adjuvant Melanoma Trial Cuts Recurrence Risk by 42%
Merck and Moderna report a 42% reduction in recurrence or death for intismeran plus KEYTRUDA in resected stage IIB-IV melanoma, with full data at ESMO 2026. #SyenzaNews #melanoma #MarketAccess

Alzheimer's Disease
FDA Launches Neuroscience Medical Product Development Program
The FDA has launched the Neuroscience Advancement and Innovation Nexus, starting with an Alzheimer’s Prevention Accelerator. #SyenzaNews #Alzheimers #MarketAccess

Artificial Intelligence And Machine Learning
Clinical AI governance framework guides AI tool evaluation
A new npj Digital Medicine article in press from SCPMG proposes the C-TACT clinical AI governance framework, with weighted lifecycle scorecards and its limits stated.

